Caribou Biosciences, Inc. (CRBU)
NASDAQ: CRBU · Real-Time Price · USD
1.100
+0.030 (2.80%)
Mar 4, 2025, 4:00 PM EST - Market closed
Caribou Biosciences Revenue
Caribou Biosciences had revenue of $2.02M in the quarter ending September 30, 2024, a decrease of -91.45%. This brings the company's revenue in the last twelve months to $11.48M, down -66.85% year-over-year. In the year 2023, Caribou Biosciences had annual revenue of $34.48M with 148.91% growth.
Revenue (ttm)
$11.48M
Revenue Growth
-66.85%
P/S Ratio
8.36
Revenue / Employee
$72,627
Employees
158
Market Cap
99.61M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 34.48M | 20.63M | 148.91% |
Dec 31, 2022 | 13.85M | 4.25M | 44.31% |
Dec 31, 2021 | 9.60M | -2.76M | -22.35% |
Dec 31, 2020 | 12.36M | 6.57M | 113.56% |
Dec 31, 2019 | 5.79M | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 400.28B |
Johnson & Johnson | 88.82B |
Merck & Co. | 64.17B |
AbbVie | 56.33B |
AstraZeneca | 54.07B |
Novartis AG | 51.72B |
Eli Lilly and Company | 45.04B |
Thermo Fisher Scientific | 42.88B |
CRBU News
- 8 days ago - Shareholders of Caribou Biosciences, Inc. Should Contact The Gross Law Firm Before February 24, 2025 to Discuss Your Rights - CRBU - PRNewsWire
- 9 days ago - INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Caribou Biosciences - Accesswire
- 12 days ago - The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of February 24, 2025 in Caribou Biosciences, Inc. Lawsuit – CRBU - GlobeNewsWire
- 13 days ago - SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Caribou Biosciences - GlobeNewsWire
- 14 days ago - Caribou Biosciences to Participate in Upcoming Investor Conferences - GlobeNewsWire
- 17 days ago - CRBU Deadline: Rosen Law Firm Urges Caribou Biosciences, Inc. (NASDAQ: CRBU) Investors to Contact the Firm for Information About Their Rights - Business Wire
- 4 weeks ago - DEADLINE REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Caribou Biosciences - GlobeNewsWire
- 7 weeks ago - Caribou Biosciences Initiates the CB-010 GALLOP Phase 1 Trial in Lupus and Provides Outlook for Multiple Clinical Datasets in 2025 - GlobeNewsWire